guest ::
| Home > In process > Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries. > print |
| Home > In process > Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries. > print |
| 001 | 285160 | ||
| 005 | 20260211160436.0 | ||
| 024 | 7 | _ | |a 10.1001/jamanetworkopen.2025.58573 |2 doi |
| 024 | 7 | _ | |a pmid:41665901 |2 pmid |
| 037 | _ | _ | |a DZNE-2026-00182 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Halbgebauer, Rebecca |b 0 |
| 245 | _ | _ | |a Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries. |
| 260 | _ | _ | |a Chicago, Ill. |c 2026 |b American Medical Association |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1770822136_28074 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a With blood-based phosphorylated tau biomarkers soon to be used for diagnosis of Alzheimer disease, analyzing tau levels in other conditions could enhance biomarker interpretability. Moreover, mechanisms of tau release into circulation remain unclear.To evaluate concentrations of phosphorylated and nonphosphorylated tau variants in the blood of patients with multiple traumatic injuries on days 0, 1, 5, and 10 and investigate biological processes driving tau release.This multiple-trauma cohort (injury severity score, ≥18) included 45 severely injured patients with (n = 27) and without (n = 18) moderate-to-severe traumatic brain injury on emergency computed tomographic imaging. Controls consisted of 24 healthy volunteers. Participants were recruited from December 1, 2013, to October 31, 2022. Blood samples were analyzed for brain-derived tau (BD-tau), total tau (t-tau), and phosphorylated tau 217 (p-tau217) and 231 (p-tau231) levels. Associations among tau concentrations, clinical data, and outcome (eg, Glasgow Coma Scale [GCS] score) were assessed. Data were analyzed from March 1, 2023, to September 30, 2024.Serum BD-tau, t-tau, p-tau217, and p-tau231 levels.A total of 214 serum samples were analyzed. Median age of the 45 patients was 48 (IQR, 33-60) years (35 [77.8%] male); median age of the 24 controls, 43 (IQR, 28-50) years (16 [66.7%] male). Median serum levels of tau variants were increased in patients with multiple traumatic injuries at day 0 compared with controls (t-tau: 43 [IQR, 21-95] vs 3 [IQR, 3-5] pg/mL; BD-tau: 78 [IQR, 30-343] vs 2 [IQR, 2-3] pg/mL; p-tau231: 61 [IQR, 21-79] vs 2 [IQR, 1-3] pg/mL; all, P < .001). Only median BD-tau levels remained elevated until day 10 (day 1, 25 [IQR, 14-69] pg/mL; day 5, 9 [IQR, 4-15] pg/mL; day 10, 8 [IQR, 4-18] pg/mL). Median tau levels at admission were higher in patients with lower GCS scores (BD-tau: 107 [ IQR, 59-838] vs 33 [IQR, 24-78] pg/mL [P = .01]; p-tau231: 76 [IQR, 36-114] vs 28 [IQR, 9-63] pg/mL [P = .02]). Elevated median tau levels were also observed in patients with hemorrhagic shock vs those without shock (eg, BD-tau on day 0: 113 [IQR, 78-378] vs 31 [IQR, 24-61] pg/mL; P = .002) and in nonsurvivors vs survivors with uncomplicated courses (eg, BD-tau on day 1: 92 [IQR, 22-527] vs 16 [IQR, 7-23] pg/mL; P = .009).In this exploratory study among a cohort of patients with multiple traumatic injuries, levels of tau variants reflected both direct and indirect neurological injury, with BD-tau showing the most persistent elevation in the acute phase. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a MAPT protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: blood |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Brain Injuries, Traumatic: blood |2 MeSH |
| 650 | _ | 2 | |a Phosphorylation |2 MeSH |
| 650 | _ | 2 | |a Cohort Studies |2 MeSH |
| 650 | _ | 2 | |a Case-Control Studies |2 MeSH |
| 700 | 1 | _ | |a Gonzalez-Ortiz, Fernando |b 1 |
| 700 | 1 | _ | |a Mayer, Benjamin |b 2 |
| 700 | 1 | _ | |a Berger, Claudius |b 3 |
| 700 | 1 | _ | |a Bergmann, Christian |b 4 |
| 700 | 1 | _ | |a Rinderknecht, Helen |b 5 |
| 700 | 1 | _ | |a Barth, Eberhard |b 6 |
| 700 | 1 | _ | |a Wohlgemuth, Lisa |b 7 |
| 700 | 1 | _ | |a Mannes, Marco |b 8 |
| 700 | 1 | _ | |a Otto, Markus |b 9 |
| 700 | 1 | _ | |a Tumani, Hayrettin |0 P:(DE-2719)9002007 |b 10 |u dzne |
| 700 | 1 | _ | |a Relja, Borna |b 11 |
| 700 | 1 | _ | |a Gebhard, Florian |b 12 |
| 700 | 1 | _ | |a Huber-Lang, Markus |b 13 |
| 700 | 1 | _ | |a Zetterberg, Henrik |b 14 |
| 700 | 1 | _ | |a Halbgebauer, Steffen |0 P:(DE-2719)9002026 |b 15 |u dzne |
| 700 | 1 | _ | |a Blennow, Kaj |b 16 |
| 773 | _ | _ | |a 10.1001/jamanetworkopen.2025.58573 |g Vol. 9, no. 2, p. e2558573 - |0 PERI:(DE-600)2931249-8 |n 2 |p e2558573 |t JAMA network open |v 9 |y 2026 |x 2574-3805 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285160/files/DZNE-2026-00182_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285160/files/DZNE-2026-00182_Restricted.pdf?subformat=pdfa |x pdfa |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 10 |6 P:(DE-2719)9002007 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)9002026 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b JAMA NETW OPEN : 2022 |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-10-18T13:36:16Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-10-18T13:36:16Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2021-10-18T13:36:16Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-09 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-09 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b JAMA NETW OPEN : 2022 |d 2024-12-09 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-09 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-09 |
| 920 | 1 | _ | |0 I:(DE-2719)5000077 |k Clinical Study Center (Ulm) |l Clinical Study Center (Ulm) |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)5000077 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|